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Abstract
Nonlinear mixed effect models (NLMEM) with multiple responses are increasingly
used in pharmacometrics, one of the main examples being the joint analysis of the
pharmacokinetics (PK) and pharmacodynamics (PD) of a drug. Efficient tools for
design evaluation and optimisation in NLMEM are necessary. The R functions PFIM
1.2 and PFIMOPT 1.0 were proposed for these purposes, but accommodate only single
response models. The methodology used is based on the Fisher information matrix,
developed using a linearisation of the model. In this paper, we present an extended
version, PFIM 3.0, dedicated to both design evaluation and optimisation for multiple
response models, using a similar method as for single response models. In addition to
handling multiple response models, several features have been integrated into PFIM 3.0
for model specification and optimisation. The extension includes a library of classical
analytical pharmacokinetics models and allows the user to describe more complex
models using differential equations. Regarding the optimisation algorithm, an
alternative to the Simplex algorithm has been implemented, the Fedorov-Wynn
algorithm to optimise more practical D-optimal design. Indeed, this algorithm optimises
design among a set of sampling times specified by the user. This R function is freely
available at www.pfim.biostat.fr. The efficiency of this approach and the simplicity of
use of PFIM 3.0 are illustrated with a real example of the joint PKPD analysis of
warfarin, an oral anticoagulant, with a model defined by ordinary differential equations.
Key words: Fisher information matrix; nonlinear mixed effect models; multiple
response models; optimal designs; D-optimality; PFIM.
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1. Introduction
Nonlinear mixed effect models (NLMEMs) are increasingly used for the analysis of
longitudinal data describing a biological process. They allow the estimation of the mean value
of parameters in population studies and their inter-individual variability. They are also used
for the joint modelling of several biological responses, such as the joint analysis of
pharmacokinetic (PK) and pharmacodynamic (PD) data [1]. Pharmacokinetics deals with the
time-course of drug concentration, whereas pharmacodynamics refers to the time-course of
drug action in the body. In pharmacometrics, analysis through a NLMEM is called the
population approach. To estimate parameters in NLMEMs, maximum likelihood estimation is
used primarily, although the likelihood for these models has no analytical solution. Specific
algorithms, implemented in several software packages, have therefore been proposed to
perform this maximisation [2].
Before the estimation step, the investigator of a study is confronted with the choice of the
design which is crucial for an efficient estimation of model parameters. A design in NLMEM,
also called a population design, is composed of the number of elementary designs (or groups)
and the specification of each elementary design and the associated number of subjects. In this
setting, the term elementary design is used to describe a collection of subjects that have
identical design characteristics defined by the number of sampling times and their allocation
in time. To evaluate and compare population designs, a statistical approach based on the
theory of optimum experimental design in classical nonlinear models and described for
instance by Atkinson and Donev [3] or by Walter and Pronzato [4] has been extended to
NLMEMs. This theory is based on the Fisher information matrix, whose inverse, according to
the Cramer-Rao inequality, is the lower bound of the variance covariance matrix of any
unbiased estimators of the parameters. Due to the lack of an analytical expression for the
likelihood in NLMEM, an exact expression of the Fisher information matrix cannot be
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4
defined. That is why an expression based on a linearisation of the model around the
expectation of random effects has been proposed by Mentré et al. [5] and extended by Retout
and Mentré [6] in the context of a single response model. The usefulness of this approach has
been demonstrated, both by simulation [7, 8] and in real pharmacokinetic studies [9, 10]. To
make the procedure more accessible to investigators, the approximate expression of the Fisher
information matrix has been implemented in the R function PFIM 1.2, which can be used for
design evaluation and comparison [11].
Regarding optimisation, two approaches can be used, either the optimisation of exact
designs or of statistical designs. In the case of optimisation of exact designs, the group
structure of the design is fixed: the number of elementary designs, the number of samples per
design and the number of subjects per elementary design are given and the design variables
used to optimise are only the sampling times. Optimisation of statistical designs consists in
optimising both the allocation of the sampling times and the whole group structure, that is to
say the number of elementary designs, the number of samples per elementary designs and the
proportion of subjects in each elementary design. An exact design is then derived by rounding
off the proportion of subjects in each elementary design. Optimisation based on the D-
optimality criterion has been implemented in the R function PFIMOPT 1.0 [12], where the
optimal design is the one that maximises the determinant of the Fisher information matrix. In
PFIMOPT 1.0, both exact or statistical optimisation can be performed using the general
Simplex algorithm [13]. It optimises the sampling times in given continuous intervals.
The main limitation of PFIM 1.2 and PFIMOPT 1.0 is that both aim at evaluating and
optimising population designs only for single response models. Moreover, the model had to
be written using an analytic expression and thus the need to use more complex models is
limited. Regarding optimisation, the Simplex algorithm is a general optimisation algorithm.
However, even if its applicability has been shown in pharmacokinetic examples [8], when
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5
there are a large number of parameters to optimise, or when the model is complex, it could
have difficulties in converging towards the optimal design and should sometimes be run again
using the optimised design as a new initial design.
Recently, the expression for the Fisher information matrix has been extended in the
context of a joint estimation of a set of parameters from multiple responses using the same
linearisation as for single response [14-16]. In that context, some parameters can be included
in several responses, as for instance in a classical PKPD model with the PD response
depending on the PK parameters That joined estimation is then more informative, obtaining
information on the PK parameters from both PK and PD responses. However, it increases the
complexity of the computation of the Fisher information matrix compared to its computation
for each response (single response). The relevance of the use of this approximation of the
Fisher information matrix for that multiple response NLMEM context has been shown by
Bazzoli et al. [14] through simulation of a PKPD model; results were very similar to those
obtained from a more exact computation of the information matrix, without any linearization,
using stochastic approximation through the SAEM algorithm of MONOLIX [17].
This expression has been implemented in PFIM 3.0, an extension of PFIM to handle both
design evaluation and optimisation in NLMEMs with multiple responses. The extension
includes a library of classical analytical pharmacokinetics models and allows more complex
models to be described using a system of differential equations. Regarding the optimisation
step, an alternative to the Simplex has been added in PFIM 3.0, the Fedorov-Wynn algorithm.
It is a specific design optimisation algorithm implemented in PFIM 3.0 for statistical
optimisation [5, 18] which has the property of converging towards the D-optimal design.
The aim of this paper is to present PFIM 3.0. In section 2, we present a nonlinear mixed
effect multiple response design and model and the expression of the population Fisher
information matrix for multiple responses. Then, the structure of PFIM 3.0 and the description
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6
of its features and use are presented in Section 3. Lastly, an example of the use of PFIM 3.0 to
design a new trial for the joint analysis of the pharmacokinetics and pharmacodynamics of
warfarin, an oral anticoagulant, is provided in Section 4.
2. Statistical methods
a. Nonlinear mixed effect multiple response design and model
A design for NLMEM, i.e. a population design, is composed of N individuals to whom
we allocate an “elementary” design iξ , 1, ,= i N . Each elementary design is defined by a
number
i
n of sampling times and their allocation in time. A population design is therefore
described by N elementary designs :
{ }1, ,Ξ =  Nξ ξ (1)
leading to a total number n of observations.
In the case of a multiple response model, an elementary design for one individual i is
composed of several sub-designs, i.e ( )1 2, , ,i i i iKξ ξ ξ ξ=  , where ikξ is the design associated
with the thk response, k = 1, …, K.
ik
ξ is defined by ( )1 2, , , ikik ik iknt t t , the vector of the ikn
sampling times for the observations of the thk response, so that
1
K
i ik
k
n n
=
= .
Usually, population designs are composed of a limited number Q of groups of
individuals. Each group is defined by an elementary design
qξ , 1, ,= q Q , which is
composed, for the thk response, of
qk
n sampling times ( )1 2, , , qkqk qk qknt t t to be performed on
a number
qN of individuals. The population design can then be noted as follows:
[ ] [ ]{ }1 1 2 2, ; , ; ; ,Q QN N Nξ ξ ξ Ξ =   (2)
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A nonlinear mixed effects multiple response model or a multiple response population
model is defined as follows. The vector of observations
i
Y for the i
th
individual is defined as
the vector of the K different responses:
1 1, , ,
T
T T T
i i i iKY y y y =   (3)
where
ik
y , 1, ,k K=  , is the vector of observations for the kth response. Each of these
responses is associated with a known function fk which defines the nonlinear structural
model. The K functions fk can be grouped in a vector of multiple response models F, such as:
( ) ( ) ( )1 1 2 2( , ) , , , , , ,
T
T T T
i i i i i i K i iKF f f fθ ξ θ ξ θ ξ θ ξ
 =
  
 (4)
where iθ is the vector of all the individual parameters needed for all the response models for
individual i. The vector of individual parameters iθ depends on , the p-vector of the fixed
effects parameters and on
i
b the vector of the p random effects for individual i. The relation
between
i
θ and ( ), ibβ is modelled by a function g , ( ),i ig bθ β= , which is usually additive,
so that = +i ibθ β , or exponential so that ( )exp=i ibθ β . It is assumed that ib ∼ ( )0,N Ω with
Ω defined as a p p× -diagonal matrix, each diagonal element 2
r
ω , 1, ,r p=  , representing
the variance of the thr component of the vector bi. We consider here only the case of a
diagonal Ω matrix with no correlation between the random effects.
The statistical model is thus given by:
( )( ), ,i i i iY F g bβ ξ ε= + (5)
where
i
ε is the vector composed of the K vectors of residual errors
ik
ε , 1, ,k K=  ,
associated with the K responses. We also suppose
ik
ε ∼ ( )0, ikN Σ with ikΣ a ik ikn n× -diagonal
matrix such that
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( ) ( )( )( )
2
int int, , , , , ,ik i erk slopek ik erk slopek k i ikb diag f g bβ σ σ ξ σ σ β ξΣ = + (6)
where
int erkσ and slopekσ qualify the model for the variance of the residual error of the
th
k response. The case 0slopekσ = returns a homoscedastic error model, whereas the case
int 0erkσ = returns a constant coefficient of variation error model. The general case where the
two parameters differ from 0 is called a combined error model. We then note
( )int, , , ,i i er slope ibβ σ σ ξΣ the variance of iε , over the K responses, such that iΣ is a i in n× -
diagonal matrix composed of each diagonal element of
ikΣ with 1, ,k K=  . slopeσ and int erσ
are two vectors of the K components
int erkσ and slopekσ , 1, , ,k K=  respectively. Finally,
depending on the value of bi, we assume that the errors iε are independently distributed.
Let  be the vector of population parameters to be estimated, i.e.
2 2
1 int( , , , , , )
T T T T
p er slopeβ ω ω σ σΨ =  and let  be the vector of variance
terms
2 2
1 int( , , , , )
T T T
p er slopeλ ω ω σ σ=  , so that ( ),T T Tβ λΨ = .
b. Fisher information matrix
The population Fisher information matrix ( ),Ψ ΞFM for multiple response models with
the population design Ξ is given by:
( )
( )2 ,
,
 	∂ Ψ
Ψ Ξ = −
 
∂Ψ ∂Ψ 
F T
L Y
M E (7)
where ( ),ΨL Y is the log-likelihood of the vector of the whole observations Y for the
population parameters .
Assuming independence across individuals, this log-likelihood can be defined as the
sum of the log-likelihoods of the vectors of observations for each individual:
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( ) ( )
1
, ,
=
Ψ = Ψ
N
i
i
L Y L Y . Therefore, taking the second derivatives, the population Fisher
information matrix for N individuals can also be defined as the sum of the N elementary
information matrices ( ),ΨF iM ξ computed for each individual i:
( ) ( )
1
, ,
=
Ψ Ξ = Ψ
N
F F i
i
M M ξ (8)
In the case of a limited number Q of groups, it is expressed as:
( ) ( )
1
, ,
Q
F q F q
q
M N M ξ
=
Ψ Ξ = Ψ (9)
The expression of an elementary Fisher information matrix for multiple responses has been
described in Bazzoli et al. [14] where further details are given. For the sake of simplicity, we
have omitted the index i for the individual in the following. The Fisher information matrix is
a block matrix depending on the approximated marginal expectation E and variance V of the
observations.
( )
( ) ( )
( ) ( )
, ,1
,
, ,2
F T
A E V C E V
M
C E V B E V
ξ
 	
Ψ ≅ 
 
 
(10)
where
1 1 1( ( , )) 2 ( )
T
ml
m l l m
E E V V
A E V V tr V V
β β β β
− − −∂ ∂ ∂ ∂= +
∂ ∂ ∂ ∂
with m and 1, ,l p= 
1 1( ( , )) ( )ml
m l
V V
B E V tr V V
λ λ
− −∂ ∂=
∂ ∂
with m and ( )1, ,diml λ= 
1 1( ( , )) ( )ml
l m
V V
C E V tr V V
λ β
− −∂ ∂=
∂ ∂
with ( )1, ,diml λ=  and 1, ,m p= 
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Note that in this work, we consider that the variance of the observations with respect to the
mean parameters is constant, i.e. ( , ) 0
ml
C E V = and 1( , ) 2 −
∂ ∂
=
∂ ∂
T
ml
m l
E E
A E V V
β β
.
3. Implementation of PFIM 3.0 using R software
The development of the population Fisher information matrix described previously has
been implemented in an extension of the R function PFIM: PFIM 3.0. It allows a design
evaluation and optimisation of multiple response population models. PFIM 3.0 can be used
for single response models instead of the previous version PFIM 1.2 or PFIMOPT 1.0. In
addition to the extension for multiple response models, options have been added for model
specification and for design optimisation. The free statistical R software (R 2.4.1 and higher
versions) [19] (http://cran.r-project.org/) is required to use PFIM 3.0. This function is freely
available on the PFIM website http://www.pfim.biostat.fr as well as an extensive
documentation and some examples to use it.
a. Model specification
In PFIM 3.0, the model has to be entered in a model file called by default model.r. It must
be specified by the user either in its analytical form or by using a system of differential
equations. This extension to a system of differential equations requires the use of the lsoda
function included in the library “odesolve” implemented by Setzer to solve the system [20]
and the fdHess function included in the library “nlme” developed by Pinheiro and Bates [21]
for numerical derivatives. The lsoda function uses a function of the same name written in
Fortran by Petzold and Hindmarsh [22, 23]. This function solves a system of differential
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equations using the Adams method, a predictor–corrector method for non-stiff systems; it uses
the BDF (Backward Differentiation Formula) for stiff systems. Regarding the function
fdHess, it evaluates an approximate gradient of a scalar function using finite differences.
Moreover, a library of standard PK models has been added. Twelve PK models are
included: one or two compartment models, with first order oral, bolus or infusion
administration and after a single dose, multiple doses or steady-state. Only models with first
order elimination are presently available in the library of PFIM 3.0. Currently, there are no
models with lag time. A list of the models and their characteristics included in the library is
given in Table 1.
b. Optimisation algorithms
An alternative to the Simplex algorithm has been added in PFIM 3.0, the Fedorov-Wynn
algorithm. It is specifically dedicated to design optimisation problems and has the property of
convergence towards the D-optimal design [5, 24, 25]. It optimises statistical designs (i.e the
group structure, the number of samples per subject and the sampling times) for a given total
number of samples. Minimum and maximum number of samples per subject are specified. To
optimise the design, it considers only a set of possible sampling times defined by the user.
This can be an advantage in clinical practice to avoid unfeasible sampling times. Design
optimisation can be constrained to the same sampling times across responses or not. It is also
possible to give each elementary design sampling times from a different set of finite sampling
times. For instance, it is possible to specify that each elementary design should include two
points among a first set of sampling times (for instance Day 1) and a third point among a
second set of sampling times (for instance Day 2). The user therefore specifies a list of
sampling windows, and for each window, the set of possible sampling times and the miminum
and maximum number of sampling times within that window. The Fedorov-Wynn algorithm
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is programmed in C code and is linked to PFIM 3.0 through a dynamic library. Moreover,
PFIM 3.0 uses the function combn in the R package “combinat” to generate all possible
elementary designs from the set of pre-specified sampling times. To start the algorithm, an
initial population design is required.
c. Input file
The inputs to PFIM 3.0 are entered in R objects by filling in one input file called by
default stdin.r. The same function PFIM 3.0 is used for the evaluation and optimisation of
population designs, which is why the user has to notify it in the input file in a specific R
object. Then, this input file is composed of two main sections of R objects. The first one is
composed of general R objects required for evaluation and optimisation such as the model
form (analytical or differential equation system), the parameterisation of the structural model,
the type of inter-individual random effect model (additive or exponential), values of int erσ
and
slope
σ for the variance error model and a priori values of the fixed effect parameters and
variance parameters. The user also specifies the population design to evaluate or, for
optimisation, an initial population design. They are defined as a group of elementary designs
each one associated with a number of subjects. The second section is dedicated to design
optimisation where the specific objects are algorithm options. First, the user specifies if the
same sampling times are required for each response or not. Then, the algorithm is chosen
(Simplex or Fedorov-Wynn). If the Fedorov-Wynn is required, the user must provide the
following information: the number of sampling windows, the list of the allowed sampling
times for each sampling window, the list of the number of allowed sampling times for each
sampling window, the maximum and minimum total number of sampling times per subject.
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Graphical representations are provided automatically if graph objects are completed. Once
the model file and the input file are filled in, the user can run the function PFIM 3.0 by calling
the function in the R Console window: PFIM ( ).
d. Output file
The results are written to an output file named by default stdout.r or with a name
specified in the input file. PFIM 3.0 returns a summary of the input, the population design
evaluated or optimised, the associated population Fisher information matrix, the standard
error expected on each parameter, the corresponding coefficient of variation (%), its
determinant and a criterion Φ defined as the determinant standardized by the dimension of
the vector Ψ : ( ) ( )( ) ( )
1
dimdet ,
F
M Ψ Φ Ξ = Ψ Ξ  . When design optimisation is performed, the
list of the algorithm options is also specified in the output file. For instance, for the Fedorov-
Wynn algorithm, the set of allowed sampling times, the number of sampling times, the
maximum and the minimum number of points for each response are returned. The optimised
design is reported with the proportion of subjects optimised by the Fedorov-Wynn algorithm
and their absolute number. If a graph has been supplied in the input file, the mean profile of
each response and the associated sampling times of the evaluated or optimised design are
represented on an R graph.
4. Illustration of design for PKPD of warfarin
We aim to illustrate the use of PFIM 3.0 for the joint PKPD modelling of the time course of
total racemic warfarin plasma concentrations and effect on prothrombin complex activity
(PCA), by designing a new trial for this joint population analysis.
To do this, we use an example extracted from a classical pharmacology study published 40
years ago, by O’Reilly et al. [26, 27] on the pharmacokinetics and pharmacodynamics of
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warfarin. Previously, these data have been fitted by Holford for the analysis of the dose-effect
relationship of warfarin [28] using nonlinear mixed effects models. This example was
presented in [29] but using different constraints in the optimisation step.
a. Population design and model
Warfarin is administered by a single oral dose of 100 mg. A one compartment model with
first order absorption and elimination adequately describes the concentration data (PK). The
PCA effect is described by a turnover model with inhibition of the input (PD). The model can
be written as a system of ordinary differential equations:
( )
( )
,
,
− ⋅= ⋅ ⋅ − ⋅ak tPK PK
a PK PK
df t CL
k D e f t
dt V
θ
θ (11)
( ) ( )
( )
( )
50
, ,
1 ,
,
 	
= − − ⋅
 
 + 
PD PD PK PK
in out PD PD
PK PK
df t f t
R k f t
dt IC f t
θ θ
θ
θ
(12)
where fPK and fPD are respectively the warfarin plasma concentrations and effect model and
PK
θ and
PD
θ the parameters needed for each response. D is the dose of warfarin. The vector
of the PK parameters is ( ), ,
T
PK a
k CL Vθ = with
a
k the absorption constant, CL the apparent
clearance and V the apparent volume of distribution. PCA is controlled by the rate of input Rin
and the output rate constant kout of the response, and its baseline value is given by the ratio of
those parameters
in out
R k . The vector of PD parameters is thus defined by
( )50, ,
T
PD in out
R IC kθ = where 50IC is the drug concentration which produces 50% of
maximum inhibition achieved at the effect site.
The inter-individual random effects are assumed to be exponential for all parameters. We
associate a proportional error for the PK model and an additive error for the PD model
characterised by the parameters
slopePK
σ and int erPDσ . Thus, the vector of population
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parameters Ψ is described by the vector of fixed effects ( )
50
, , , , ,
a in out
T
k CL V R IC kβ β β β β β β= and
by Tλ the vector composed of the variance of the random effects and of the parameters for the
error models such that ( )
50
2 2 2 2 2 2
int, , , , , , ,a in out
T
k CL V R IC k slopePK erPDλ ω ω ω ω ω ω σ σ= .
Values of the parameters are those obtained by Holford performing the simultaneous
PKPD population analysis of warfarin. The population parameters were estimated by
maximum likelihood, with the NONMEM software [30]. They are given in Table 2.
b. Design optimisation for a new study
Using PFIM3.0, we first evaluate the design used in the previous study to determine the
joint population PKPD model. We call this design the “empirical design” denoted
emp
Ξ . It
involves one group of 32 healthy volunteers, with 13 sampling times at 0.5, 1, 2, 3, 6, 9, 12,
24, 36, 48, 72, 96, 120 hours for warfarin concentration measurements and 8 sampling times
at 0, 24, 36, 48, 72, 96, 120, 144 hours for PCA measurement.
emp
Ξ thus has a total of 672
measurements.
We then optimise two population designs under several constraints using the Fedorov-
Wynn algorithm implemented in PFIM 3.0. To do that, we first optimise a population design
_opt idenΞ with only four sampling times per elementary design common to both responses.
This optimisation step is performed on the same number of 32 volunteers and the set of
admissible sampling times is the set of times used in the empirical design except times 1 and 3
for PK. We then optimise a population design _opt diffΞ , with four sampling times per
elementary design, but now, the optimal sampling times can be different for each response.
c. Results
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Fig. 1 reports the model file used for the design evaluation and optimisation of the joint
PKPD model of warfarin. The input file of PFIM 3.0 for the evaluation of
emp
Ξ is reported in
Fig. 2. The output file of PFIM 3.0 for the optimal design
_opt idenΞ and the associated R graph
output are represented in Fig. 3 and Fig. 4, respectively. The optimal designs with their
associated criterion are reported in Table 3.
emp
Ξ and both optimal designs ( _opt idenΞ , _opt diffΞ )
are different by their group structure. _opt idenΞ and _opt diffΞ are composed of two elementary
designs compared to only one for
emp
Ξ . The Fedorov-Wynn algorithm optimises proportions
of subjects, to be practical those numbers are then rounded to the nearest integers. Each
elementary design involves 22 and 10 subjects for _opt idenΞ and 29 and 3 for _opt diffΞ . In order
to get more practical designs, _opt diffΞ is simplified in a new design _ _opt diff simpΞ , composed of
one group of 32 subjects, meaning that the 3 subjects originally included in the second
elementary design have been added to the first elementary design. The two optimised designs
have a smaller number of samples than the empirical design and are therefore less efficient
with lower criterion values (Table 3). These two designs include a sample at 144 hours for the
PK measurement whereas this sample is not present in the empirical design. Indeed, in
population PK studies, when a proportional residual error is associated with the model, the
optimal design includes the latest time among those proposed. In our case, for optimisation,
we allowed the sample at 144 hours both for PK and PD responses.
In order to get an efficiency similar to that obtained with
emp
Ξ , we then derived two
“enlarged” designs _ _opt iden enlΞ and _ _ _opt diff simp enlΞ from the two optimal designs by increasing
the number of subjects. 55 subjects and 52 subjects are involved in _ _opt iden enlΞ and
_ _ _opt diff simp enlΞ , meaning a total of number of sampling times of 440 and 416, respectively.
The expected relative standard errors (RSE) of
emp
Ξ , _ _opt iden enlΞ and _ _ _opt diff simp enlΞ , i.e
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standard error divided by the true value of the parameter, their total number of sampling times
and the associated criterion are given in Table 4.
The evaluation of
emp
Ξ returns expected RSEs smaller than 30%, except for the variance
parameters
50
2
IC
ω and 2
outk
ω , where they are rather large (about 68% and 41%) due to the small
inter-subject variability of these parameters. Comparison between both “enlarged” designs
shows that only the coefficient of variation of the estimation of the variance parameter
50
2
IC
ω is
increased compared to
emp
Ξ . The expected RSE on the terms for residual errors increase in
both optimal designs, but they remain lower than 10%. For other parameters, the results from
design optimisation, in terms of precision of estimation, are very close to those obtained with
the empirical design, although “enlarged” designs involve only 440 and 416 measurements,
respectively, 35% and 38% fewer than the empirical design. This sample reduction, together
with a similar efficiency, leads to a more ethical and less costly study. Using PFIM 3.0, we
find new efficient designs to study the joint PKPD of warfarin fitting to different clinical
constraints.
5. Discussion
In this paper, we consider the R function PFIM 3.0, an extension of the R functions PFIM
1.2 and PFIMOPT 1.0, allowing evaluation and optimisation of designs for nonlinear mixed
effect models with multiple responses. The methodology is based on the Fisher information
matrix, developed using a linearisation of the model, as proposed for a single response by
Mentré et al. [5] and extended for multiple responses [14-16]. In addition to handling multiple
response models, several features have been integrated in PFIM 3.0. First, regarding the
model specification, it can now be specified as a system of differential equations; this is an
alternative to analytical model specification, particularly useful for complex models. For
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“classical” pharmacokinetic models, a library of twelve pharmacokinetic models is available.
Concerning the optimisation algorithm, the Fedorov-Wynn algorithm has been added as an
alternative to the general Simplex algorithm to optimise more practical D-optimal designs [24,
25]. Indeed, this algorithm allows design optimisation with fixed sampling times specified by
the user which can be a great advantage with respect to medical constraints. This algorithm
optimises the sampling times, which can be different or imposed to be identical across
responses, but also optimises the group structure, using the approach of statistical designs. In
addition to convergence issues using the Simplex algorithm compared to the Fedorov-Wynn
[18], optimisation within continuous intervals of times can be more questionable: the Simplex
algorithm can, sometimes for a long time, pursue the optimisation by exchanging at each
iteration one or several sampling times by some others which differ from the previous by only
few seconds. This greatly slows down the whole optimisation process and has no relevance in
clinical practice.
We illustrate the different options of this new extension of PFIM using a real example of
the simultaneous population analysis of the time course of warfarin concentration and its
effect on the prothrombin complex activity after single dose administration. We optimise and
derive two population designs using the Fedorov-Wynn algorithm, either imposing the same
sampling times across responses or not, and we compare them to an “empirical design” used
in the previous study of warfarin [26, 27]. Globally, the expected precision of estimations are
in the same range for the three designs, even if the number of samples per patient, and thus,
the total number of samples are considerably reduced (38% fewer samples in the optimised
designs compare to the empirical one). In this example, we show the interest of the
optimisation procedure implemented in PFIM 3.0 from a medical, economic as well as ethical
point of view. This approach can also be used for other complex modelling, such as the
pharmacokinetics of a parent drug and its metabolite [31]. However, in some situations, due to
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the different time scales of the pharmacokinetic profiles between the parent drug and the
metabolite, different sampling times for the two responses may be required. It should be noted
however, using the Fedorov-Wynn algorithm under this assumption, the number of possible
elementary designs will be large and can considerably increase the computation time and the
memory requirement. Limiting the number of allowed sampling times for each sampling
window also helps to avoid computational issues.
In the example, the prothrombin complex activity is controlled by the rate of input Rin and
the output rate constant kout of the response, and the initial condition is given by the ratio of
these parameters
in out
R k . It would be possible by using a modification of the
parameterisation of the model to estimate the initial condition and Rin or kout or even to fix the
initial condition (for instance to 100%) and to estimate only Rin or kout .
The present development of the Fisher information matrix for multiple response models
takes into account all the population parameters to be estimated. Another approach would
have been to optimise separately one design for the PK parameters and one for the PD
parameters, fixing the PK parameters to their mean in the population (sequential approach).
However, this approach can be sub-optimal as no variability on the PK parameters is taken
into account in the PD model. For instance, we compared this sequential approach to the one
used in this paper, using the same example and similar constraints. We obtained the same
optimal design for the PK model. Regarding the conditional D-optimal design for the PD, the
design is quite different from _ _opt diff simpΞ . Indeed, it involves two elementary designs with
sampling times at (0, 24, 72, 96) and (0, 24, 36, 96) hours, and with 21 and 11 subjects,
respectively. Comparison of the relative standard errors shows an increase by at least a factor
2 with this design compared to those obtained with
_ _opt diff simpΞ .
Following the first theoretical work on optimal design for NLMEM, this research theme
has grown rapidly both in methodological and application developments. An email mailing
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list server PopDesign is now available for questions and comments about the experimental
design of any study for which nonlinear mixed effect modelling is proposed for the analysis.
Since the first tool PFIM [11], there are now several different software tools that implement
an evaluation of the Fisher information matrix for population PK and PD models and propose
optimisation of the experimental designs (PFIM, PopDes, PopED, WinPOPT) [32]. All
software packages have ongoing development and have specific features according to the
needs and goals of the research teams that developed them. PFIM is the only one using the R
software.
PFIM 3.0 uses an approximate Fisher information matrix to evaluate and optimise design.
This approximation, using a linearisation of the model, may be a limitation. Indeed, even if
the relevance of this approximation has been shown by comparison to an exact Fisher
information matrix using a simulation study, the PKPD model used was very simple [14] and
may not be generalised to any complexity of the models. On the other hand, use of more
exact methods can be computationally intensive and thus time consuming. Their need is thus
questionable for nonlinear models for which design evaluation and optimisation require some
a priori values of the parameters to be estimated, which are often not known precisely.
In parallel to PFIM 3.0, PFIM Interface 2.1, a graphical user interface version of PFIM 1.2
and PFIMOPT 1.0 has been recently proposed, allowing both design evaluation and
optimisation but only for single response models. PFIM Interface 2.1 has the same features
for model specification and optimisation algorithm as in PFIM 3.0. PFIM Interface will soon
be extended to accommodate multiple response models.
In addition to the new features added in PFIM 3.0, several other extensions are planned.
First, the current library includes only pharmacokinetic models. Extensions to the usual
pharmacokinetic-pharmacodynamic models are planned, even if model specification for
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multiple responses is quite simple for the user as shown in the illustration using a system of
differential equations.
Then, the next version could integrate the computation of the Fisher matrix for a non-
diagonal variance of the random effects, as, in practice, one may want to allow correlation
between the random effects. Expression of the Fisher information matrix has been proposed in
this case for single response in Mentré et al. [5] and for multiple responses in Ogungbenro et
al. [33] but has not been yet implemented in PFIM 3.0.
Afterwards, an extension of PFIM is envisaged to implement the expression of the Fisher
information matrix for models including fixed effects for the influence of covariates on the
parameters [6], and thus, to compute the predicted power of the Wald test to detect a covariate
effect as well as the number of subjects needed to achieve a given power [18].
Moreover, Retout et al. [12] have recently used a modified version of PFIM for the
problem of design optimisation using cost functions. They focus on the relative feasibility of
the optimised designs, in terms of sampling times and of numbers of subjects. To do that the
Fedorov-Wynn algorithm has been extended to include cost functions to penalize less feasible
designs. An illustration of this extension of design optimisation to a joint population model of
infliximab and methotrexate pharmacokinetics administered in rheumatoid arthritis was
performed. The possibility of specifying user-defined cost-functions will be available in the
next version of PFIM.
The implementation of the Fisher information matrix for multiple response models
proposed in PFIM 3.0 is a relevant computing tool for the evaluation and comparison of
designs in the spreading development of multiple response PK studies. PFIM 3.0 is
distributed under the terms of the GNU GENERAL PUBLIC LICENSE (GNU GPL) Version
2, June 1991 and has been registered at the Agency for the Protection of Programs (APP) in
2008, at Paris, France.
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PFIM functions, including their extensive documentation and examples to use them, are
freely available from the PFIM website: http:/www.pfim.biostat.fr.
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Legends for Figures:
Fig. 1: Model file of PFIM 3.0 for the evaluation of the empirical design
emp
Ξ and
optimisation of both optimal designs _opt idenΞ and _opt diffΞ for the joint PKPD modelling of
warfarin.
Fig. 2: Input file of PFIM 3.0 in the context of the evaluation of the empirical
design
emp
Ξ for the joint PKPD modelling of warfarin.
Fig. 3: Input file of PFIM 3.0 in the context of the optimisation of the optimal design
_opt idenΞ using the Fedorov-Wynn algorithm for the joint PKPD modelling of warfarin.
Fig. 4: R graph output of the concentration and effect profiles versus time for the mean
parameter values used in the joint PKPD modelling of warfarin using PFIM 3.0. PK sampling
times and PD sampling times for the optimal design _opt idenΞ for each response are displayed
using number values (i.e. 1 and 2 for samples from first and second elementary design,
respectively).
28
Table 1. List of pharmacokinetic models included in the library of models of PFIM 3.0. The table includes all information needed in order to use
the model function chosen: the name, the type of input, the number of compartments and the parameters used.
Name Input
Number of
compartment
Parametrisation
bolus_1cpt_Vk IV-bolus 1 V, k
bolus_1cpt_VCl IV-bolus 1 V, Cl
infusion_1cpt_Vk IV-infusion 1 V, k
infusion_1cpt_VCl IV-infusion 1 V, Cl
oral1_1cpt_kaVk 1st order 1 ka, V, k
oral1_1cpt_kaVCl 1st order 1 ka, V, Cl
bolus_2cpt_Vkk12k21 IV-bolus 2 V, k, k12, k21
bolus_2cpt_ClV1QV2 IV-bolus 2 Cl, V1, Q, V2
infusion_2cpt_Vkk12k21 IV-infusion 2 V, k, k12, k21
infusion_2cpt_ClV1QV2 IV-infusion 2 Cl, V1, Q, V2
oral1_2cpt_kaVkk12k21 1st order 2 ka, V, k, k12, k21
oral1_2cpt_kaClV1QV2 1st order 2 ka, Cl, V1, Q, V2
Table
29
Table 2. Population parameter values estimated by the PKPD joint modelling of warfarin
Parameters Fixed effects
()
Inter-subject variability
(
2
)
ka (h
-1
) 1.60 0.701
CL (L/h) 0.133 0.063
V (L) 7.95 0.020
Rin (%/h) 5.41 0.190
IC50 (mg/L) 1.20 0.013
kout (h
-1
) 0.056 0.016
slopePK
σ 0.20 -
int erPDσ (%) 3.88 -
Table
30
Table 3. Optimal population designs for the joint model of warfarin concentration (PK) and the effect on prothrombin complex activity (PD)
according to different constraints.
emp
Ξ is the empirical design. _opt idenΞ and _opt diffΞ are both optimal designs. _ _opt diff simpΞ is a design derived
from
_opt diffΞ to be simpler. For each design, the number of elementary designs, the rounded number of subjects with the elementary design, the
sampling times for each response, the total number of sampling times and the associated criterion value are reported.
Number of
elementary
designs
Sampling times for each response
(hours)
Rounded
number of
subjects
Total
number of
sampling
times
Criterion
value
Φ
PK PD
emp
Ξ 1 0.5, 1, 2, 3, 6, 9, 12, 24, 36, 48, 72, 96,120 0, 24, 36, 48, 72, 92, 120, 144 32 672 984.20
_opt idenΞ 2 0.5, 12, 24, 144
0.5, 24, 120, 144
0.5, 12, 24, 144
0.5, 24, 120, 144
22
10
256 580.19
_opt diffΞ 2 0.5, 6, 9, 144
0.5, 6, 9, 144
0, 12, 24, 120
0, 24, 96, 120
3
29
256 607.86
_ _opt diff simpΞ
1 0.5, 6, 9, 144 0, 24, 96, 120 32 256 607.32
Table
31
Table 4. Relative standard errors (RSE) (%) computed by the population Fisher information matrix for designs
emp
Ξ and for the enlarged
designs
_ _opt iden enlΞ and _ _ _opt diff simp enlΞ derived from the two optimal designs by increasing the number of subjects in order to get a similar
efficiency obtained with
emp
Ξ . The total number of sampling times and the criterion value associated with each design are also reported.
Expected RSE (%)
ak
β
CL
β
V
β
inR
β
50IC
β
outk
β 2
ak
ω 2
CLω
2
Vω
2
inR
ω
50
2
ICω
2
outk
ω slopePKσ int erPDσ
Total
number
of
sampling
times
Criterion
value
Φ
emp
Ξ 15.7 4.6 2.9 8.0 3.3 2.9 28.0 26.3 33.0 26.2 68.3 40.8 3.9 5.6 672 984.2
_ _opt iden enlΞ 12.5 3.7 3.1 6.1 3.4 2.3 22.4 21.1 45.1 20.2 98.0 34.9 8.2 9.1 440 997.2
_ _ _opt diff simp enlΞ 12.7 3.8 2.8 6.3 3.2 2.6 22.9 21.8 38.9 20.8 83.6 41.7 8.8 9.4 416 987.5
Table
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